The estimated Net Worth of Ai, Inc. Tempus is at least $75.7 Milione dollars as of 16 August 2024. Ai Tempus owns over 3,500,000 units of Personalis Inc stock worth over $75,676,860 and over the last few years Ai sold PSNL stock worth over $0.
Ai has made over 1 trades of the Personalis Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Ai bought 3,500,000 units of PSNL stock worth $17,745,000 on 16 August 2024.
The largest trade Ai's ever made was buying 3,500,000 units of Personalis Inc stock on 16 August 2024 worth over $17,745,000. On average, Ai trades about 3,500,000 units every 0 days since 2024. As of 16 August 2024 Ai still owns at least 12,718,800 units of Personalis Inc stock.
You can see the complete history of Ai Tempus stock trades at the bottom of the page.
Ai's mailing address filed with the SEC is 600 WEST CHICAGO AVENUE, SUITE 510, CHICAGO,, IL, 60654.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci e Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: